| Size | Price | Stock |
|---|---|---|
| 5mg | $190 | In-stock |
| 10mg | $360 | In-stock |
| 50 mg | Get quote | |
| 100 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-N2099 |
| M.Wt: | 1573.67 |
| Formula: | C75H112O35 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
Onjisaponin B is an orally active natural product derived from Polygala tenuifolia. Onjisaponin B inhibits NF-κB p65. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin. Onjisaponin B reduces β-amyloid (Aβ) production. Onjisaponin B reduces radiation-induced cell apoptosis. Onjisaponin B has anti-oxidant and anti-inflammatory activities. Onjisaponin B can be used for neurological disease and radiation injury study, and its metabolite tenuifolin (TF) can enter the brain through the BBB[1][2][3][4].
In Vitro: Onjisaponin B (3-50 μM, 8-24 h) activates autophagy through an Atg7, AMPK-mTOR dependent manner in PC-12 cells[1].
Onjisaponin B (6.25-50 μM, 16-24 h) enhances the clearance of mutant huntingtin and A53T α-synuclein, lowers the toxicity and acts as a neuroprotective agent in PC-12 cells, and reduces oligomerization of α-synuclein in HeLa cells[1].
Onjisaponin B (0.01-10 μM) reducesβ-amyloid (Aβ) production with an IC50 of 10 μM without affecting BACE1 or γ-secretase activity in 293T cells[3].
Onjisaponin B (20 μg/mL, 8-50 h) inhibits the activation of Cas3 through p65, reducing radiation-induced cell apoptosis and helping to prevent radiation injury in TC, V79 and MTEC-1 cells[4].
In Vivo: Onjisaponin B (40 mg/kg; i.g.; once) cannot pass through the blood-brain barrier (BBB), but its metabolite tenuifolin (TF) can enter the brain through the BBB in mice[2].
Onjisaponin B (20-40 mg/kg; i.g.; daily for 12 days) ameliorates dopaminergic (DA) neurodegeneration in a MPTP (HY-15608)-induced mouse model of Parkinson’s disease (PD) through anti-oxidant and anti-inflammatory activities mediated via the RhoA/ROCK2 signaling pathway[2].
Onjisaponin B (10 mg/kg; p.o.; daily from 4 to 7 months of age) reduces β-amyloid production and improve cognitive impairments in transgenic mice[3].
Onjisaponin B (2.5 mg/kg; p.o.; 4 days prior to irradiation) significantly reduces pathological changes and apoptosis and the nuclear translocation of p65 in the lung tissue of p65+/- mice following radiation[4].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.